Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period and specifying the contract end date to December 31, 2028, at the customer’s request regarding the contract manufacturing agreement originally disclosed on August 14, 2018. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-12-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period for the contract period until after December 31, 2026, at the customer’s request regarding the contract manufacturing agreement with Ichnos Sciences originally disclosed on June 1, 2018. 📊 [Key Disclosure Details & Financial Figures]…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract (Voluntary Disclosure) / 2025-11-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN announced that it is scheduled to receive a milestone payment of USD 15M (approx. KRW 21.94B) following the European marketing authorization of Keytruda SC applied with ALT-B4 licensed to MSD. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] ALTEOGEN (196170) – Receipt of Milestone Payment Related to ALT-B4 License Agreement / 2025-11-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has announced the listing of new contract months for stock futures and stock options starting November 25, 2025, following the company’s listing change on the KOSPI market after its corporate spin-off. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Samsung Biologics (207940) – Information Disclosure / 2025-11-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has announced the valuation price (KRW 1,221,000) and the reference price determination method for its listing change following corporate spin-off (surviving entity), applicable on November 24, 2025. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying the Officially…

Read More “[Disclosure] Samsung Biologics (207940) – Information Disclosure / 2025-11-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period and the contract period disclosure timeline to December 31, 2026, at the customer’s request regarding the contract manufacturing agreement with Sun Pharma Global FZE originally disclosed on July 4, 2017. 📊 [Key Disclosure Details…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the details of its listing change scheduled for November 24, 2025, following a corporate spin-off, along with the lifting of trading suspension on the same date. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying the…

Read More “[Disclosure] Samsung Biologics (207940) – Information Disclosure / 2025-11-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has announced a future facility investment plan worth up to KRW 700.0B to expand its US manufacturing capacity to a total of 132,000L in response to US pharmaceutical tariffs and growing product demand. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] Celltrion (068270) – Future Business and Management Plans (Fair Disclosure) / 2025-11-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has entered into a platform technology licensing agreement with Korean biotech TRiOar for its tumor microenvironment-selective activation platform ‘TROCAD™’, securing exclusive development rights for up to 6 targets worth up to approx. KRW 522.0B including upfront and milestone payments. 📊 [Key Disclosure Details & Financial…

Read More “[Disclosure] Celltrion (068270) – Execution of Platform Technology License Agreement with TRiOar / 2025-11-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period, specifying the contract end date, and updating the counterparty disclosure schedule to August 1, 2031, at the customer’s request regarding the contract manufacturing agreement originally disclosed on November 28, 2019. 📊 [Key Disclosure Details…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-13” »